|
|
| Source: PR Newswire 05-25-2022 06:00:17 |  ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Sylvain Roy as chief technology officer. In this role, he will oversee technical operations and product quality across the company.
Read All |
| | | | | | | | |
|
